PDCD1 and neoplasm: Among active immunotherapies, ICIs have gained importance by blocking key immunosuppressive molecules, such as programmed cell death 1 (PD-1) or its ligand PD-L1, enabling cytotoxic T cells to attach tumor cells more effectively [5].